No. 052 · Combos · Peptide Blend
CJC-1295 no DAC + Ipamorelin
Also known as: Mod GRF 1-29 + Ipamorelin
- Not approved as a combo
- WADA ✗ S2
Combos are blends of separate compounds, so there is no single sequence. This ring motif is decorative — open a component for its fingerprint.
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
Not ranked: combinations have no published studies of their own. See the components below.
A PubMed search found no published studies of this combination; only reviews mention it. Ipamorelin has small human pharmacology studies; published human data on CJC-1295 without DAC (modified GRF 1-29) are scarce.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Routes studied
- Subcutaneous, Intramuscular Routes used in published research
- FDA
- Not approved as a combination
- WADA
- Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
Overview
A pulsatile GH secretagogue stack combining short-acting modified GRF with Ipamorelin for physiological GH pulses that more closely mimic natural secretion patterns.
Research status No published studies of the combination; ipamorelin has small human pharmacokinetic studies, while published human data on modified GRF 1-29 (CJC-1295 without DAC) are scarce
Mechanism
This blend pairs a short-acting GHRH analog (modified GRF 1-29, half-life ~30 min) with the selective GHRP ipamorelin to produce amplified but physiologically pulsatile GH release. The GHRH component activates cAMP/PKA on somatotrophs while ipamorelin activates IP3/PKC via the ghrelin receptor. The short duration preserves natural GH pulse patterns and feedback.
Effects reported in research
These outcomes are attributed to the individual components. The combination itself has not been studied.
- Pulsatile natural-pattern GH release
- Improved sleep onset and depth
- Reduced body fat with lean mass preservation
- Synergistic GHRH/GHRP amplification
Safety & unknowns
Human safety data are limited: ipamorelin has small human studies, while modified GRF 1-29 has very little published human data. A short-acting profile is expected to cause less sustained IGF-1 elevation than the DAC version. Reported side effects of GH secretagogues include flushing, headache, and mild water retention. Not FDA-approved.
Unknowns. The combination itself has not been studied; interactions between its components are unknown.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [2]
- Clinical trial 1999
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Dose-escalation study of the ipamorelin component in healthy men: half-life about 2 hours, with a single episode of GH release peaking at about 40 minutes.
- Preclinical 1998
Ipamorelin, the first selective growth hormone secretagogue
Rat and swine study on the ipamorelin component: GH release comparable to GHRP-6 without the ACTH or cortisol rises seen with GHRP-6 and GHRP-2.
Components
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- Gobburu et al. 1999 — ipamorelin PK/PD in human volunteers pubmed.ncbi.nlm.nih.gov
- Review of GH–IGF-1 axis performance-enhancing peptides (Front Endocrinol 2026) pubmed.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List — S2.2.4 GHRH analogues and GH secretagogues wada-ama.org
Cite this entry
peptidemeta. (2026). CJC-1295 no DAC + Ipamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/cjc-1295-no-dac-ipamorelin/
@misc{peptidemeta-cjc-1295-no-dac-ipamorelin,
title = {CJC-1295 no DAC + Ipamorelin},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/cjc-1295-no-dac-ipamorelin/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.